USA flag logo/image

An Official Website of the United States Government

Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43AI104066
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA12-090
Small Business Information
ENANTIGEN THERAPEUTICS, INC.
3805 OLD EASTON RD DOYLESTOWN, PA 18902-8400
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Development of Fluorinated Sulfamoylbenzamide Derivatives as Antiviral Agents aga
Agency: HHS
Contract: 1R43AI104066-01
Award Amount: $294,674.00
 

Abstract:

DESCRIPTION (provided by applicant): This is a phase I proposal to determine the feasibility of developing newly discovered fluorinated sulfamoylbenzamide (FSBA) derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, which is essential for the subsequent viral DNA synthesis. Distinct from the mechanism of the currently FDA-approved antiviral nucleos(t)ide analogues that inhibit HBV DNA polymerase, pgRNA assembly into nucleocapsid represents a novel therapeutic target and the FSBA compounds should thus complement the current antiviral medications. Through an extensive structure-activity-relationship (SAR) study, we have now obtained FSBA compounds with nanomolar antiviral activity. In this Phase I project, we propose to advance lead FSBA compounds with the most favorable ADME, safety and pharmacokinetics (PK) profiles for antiviral efficacy study in the HBV transgenic mouse model in vivo. Having confirmed the in vivo antiviral efficacy in the transgenic mice model, we will further evaluate the safety profile and antiviral efficacy of the lead FSBAs in HBV infected human chimeric uPA-SCID mice model in Phase II study. At the endof Phase II, we will advance one lead candidate for extensive IND enabling studies, and prepare a case for human clinical trial. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: This is a proposal to develop the newly discovered inhibitors of hepatitis B virus (HBV), fluorinated sulfamoylbenzamide derivatives, into a drug for treatment of chronic hepatitis B. The drug candidate functions through interfering with incorporation of pregenomic RNA, the template for viral DNA synthesis, into nucleocapsids, which is a distinct target from the currently FDA-approved anti-HBV medications. Hence, the drug may be of use by itself or in combination with current medications to achieve extended clinical benefits.

Principal Investigator:

Xiaodong Xu
215-589-6350
michaelxu@enantigen.com

Business Contact:

Xiaodong Xu
215-589-6350
michaelxu@enantigen.com
Small Business Information at Submission:

ENANTIGEN THERAPEUTICS, INC.
3805 OLD EASTON RD DOYLESTOWN, PA 18902-8400

EIN/Tax ID: 126156958
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No